

1 **Early Detection of Emerging SARS-CoV-2 Variants of Interest** 2 **for Experimental Evaluation**

3

4 Zachary S. Wallace^{1,2}, James Davis^{3,4}, Anna Maria Niewiadomska¹, Robert D. Olson^{3,4}, Maulik Shukla^{3,4},
5 Rick Stevens^{5,6}, Yun Zhang¹, Christian M. Zmasek¹, Richard H. Scheuermann^{1,7,8,9*}

6

7 ¹ Department of Informatics, J. Craig Venter Institute, La Jolla, CA, 92037, USA

8 ² Department of Computer Science and Engineering, University of California, San Diego, CA, 92039, USA

9 ³ Division of Data Science and Learning, Argonne National Laboratory, Lemont, IL, USA

10 ⁴ University of Chicago Consortium for Advanced Science and Engineering, University of Chicago,
11 Chicago, IL, USA

12 ⁵ Computing Environment and Life Sciences, Argonne National Laboratory, Argonne, IL, 60439, USA

13 ⁶ Department of Computer Science, University of Chicago, Chicago, IL 60637, USA

14 ⁷ Department of Pathology, University of California, San Diego, CA, 92093, USA

15 ⁸ Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, 92037, USA

16 ⁹ Global Virus Network, Baltimore MD, 21201, USA

17

18 *Correspondence: Richard Scheuermann, rscheuermann@jcvl.org

19 Key Words: SARS-CoV-2, variants of concern, Omicron, Delta, viral evolution, genomic surveillance,
20 early detection, bioinformatics

21

22

23

24 **Abstract**

25 Since the beginning of the COVID-19 pandemic, SARS-CoV-2 has demonstrated its ability to
26 rapidly and continuously evolve, leading to the emergence of thousands of different sequence
27 variants, many with distinctive phenotypic properties. Fortunately, the broad availability of next
28 generation sequencing (NGS) technologies across the globe has produced a wealth of SARS-
29 CoV-2 genome sequences, offering a comprehensive picture of how this virus is evolving so
30 that accurate diagnostics and reliable therapeutics for COVID-19 can be maintained. The
31 millions of SARS-CoV-2 sequences deposited into genomic sequencing databases, including
32 GenBank, BV-BRC, and GISAID are annotated with the dates and geographical regions of
33 sample collection, and can be aligned to the Wuhan-Hu-1 reference genome to extract the
34 constellation of nucleotide and amino acid substitutions. By aggregating these data into concise
35 datasets, the spread of variants through space and time can be assessed. Variant tracking
36 efforts have focused on the spike protein due to its critical role in viral tropism and antibody
37 neutralization. To identify emerging variants of concern as early as possible, we developed a
38 computational pipeline to process the genomic data from public databases and assign risk
39 scores based on both epidemiological and functional parameters. Epidemiological dynamics
40 are used to identify variants exhibiting substantial growth over time and across geographical
41 regions. In addition, experimental data that quantify Spike protein regions critical for adaptive
42 immunity are used to predict variants with consequential immunogenic or pathogenic impacts.
43 These growth assessment and functional impact scores are combined to produce a *Composite*
44 *Score* for any set of Spike substitutions detected. With this systematic approach to routinely
45 score and rank emerging variants, we have established a method to identify threatening variants
46 early and prioritize them for experimental evaluation.

47

48

49 **Introduction**

50 The ongoing evolution of SARS-CoV-2 has remained a persistent public health challenge
51 throughout the entire course of the pandemic. In just two and a half years since the first strain
52 of the virus was isolated and fully sequenced, SARS-CoV-2 has evolved into hundreds of
53 thousands of strains containing unique combinations of mutations, also known as variant
54 constellations, with many of these mutations leading to altered virus phenotypes in terms of
55 antigenicity, transmissibility, and viral fitness.^{25,26} In order to label the rapidly growing collection

56 of variants, the scientific community has relied on the PANGO Lineage²¹ nomenclature or WHO
57 classifications as naming schemes for these variants. The continual emergence of SARS-CoV-2
58 variants has caused public health agencies to categorize these lineages depending on their
59 predicted importance. In the United States, the CDC has identified these as four categories:
60 *Variants Being Monitored (VBM)*, *Variants of Interest (VOI)*, *Variants of Concern (VOC)*, or
61 *Variants of High Consequence (VOHC)*. Classification is dependent on viral growth dynamics
62 and level of threat to preexisting immunity or therapeutic efficacy. Notable *Variants of Concern*
63 include B.1.1.7 (WHO class Alpha), B.1.617.2 (WHO class Delta), and the most recent
64 B.1.1.529/BA.1-BA.5 (WHO class Omicron).²⁷

65 It has been a consistent pattern throughout the course of the pandemic for SARS-CoV-2 to
66 acquire genetic changes of functional and epidemiological importance, beginning with the
67 observation as early as Spring 2020 that the Spike protein mutation, D614G, was associated
68 with higher viral loads and was under positive selection.¹⁶ Since then, with the emergence of
69 Alpha and Delta, Spike mutations such as N439R, N501Y, E484K, and P681H, have been
70 linked to increased ACE2 binding affinity, antibody binding escape, and enhanced viral
71 replication.^{3,29,32} The most recently emerged *Variant of Concern*, Omicron, has been reported
72 to contain constellations of mutations across the n-terminal domain (NTD) and receptor binding
73 domain (RBD). This has resulted in high levels of viral antigenic escape, and partial or complete
74 resistance to the majority of available therapeutic monoclonal antibodies and, to a large extent,
75 infection or vaccine-elicited polyclonal sera.^{14,30} The astonishing ability of SARS-CoV-2 to
76 rapidly evolve into variants with expanded cellular tropism, enhanced replication, increased
77 transmissibility, and evasion of preexisting immunity has triggered the scientific community to
78 band together and critically monitor the evolution of this virus through efforts like the US
79 National Institute of Allergy and Infectious Diseases (NIAID)'s SARS-CoV-2 Assessment of Viral
80 Evolution (SAVE) program¹ and COVID-19 Genomics UK Consortium (COG UK), which seek to
81 iteratively provide a risk-assessment of emerging variants of interest and offer
82 recommendations towards an optimal public health response.

83 A key component to successfully monitoring viral evolution, and thereby setting the stage for
84 risk assessment, is through genomic surveillance.^{12,16} Thanks to the growing availability of next
85 generation sequencing (NGS) technologies, SARS-CoV-2 genome sequences from millions of
86 infected individuals across the globe have been determined and deposited into public
87 databases¹¹ such as the National Center for Biotechnology Innovation (NCBI) GenBank, the
88 Global Initiative on Sharing Avian Influenza Data (GISAID)²⁰, and the Bacterial and Viral

89 Bioinformatics Resource Center (BV-BRC)²⁴. These data have been dynamically growing at a
90 rapid pace since the early stages of the pandemic and have allowed researchers to pinpoint
91 mutations under positive or negative selection through the evaluation of occurrence rates of
92 synonymous versus non-synonymous nucleotide substitutions or identify the mutational drivers
93 of evolution by modeling growth as a linear combination of the effects of individual
94 mutations.^{15,31} Overall, the amount of SARS-CoV-2 genomic sequencing being carried out on a
95 global scale and the bioinformatics capabilities to understand these data has opened
96 opportunities for diverse research into strategies for the *early detection of emerging variants of*
97 *concern*. This is a concept by which computational frameworks are used to manage and
98 analyze rapidly growing viral sequencing data and ultimately prioritize emerging variants based
99 on epidemiological dynamics and functional characteristics in near real time^{1,15,17}. The concept
100 of *early detection* is a key aspect of the NIAID SAVE program - to select and prioritize the
101 variants for *in vitro* and *in vivo* experimentation to assess risk of novel emerging variants (see
102 Reference #1 for a complete description of the NIAID SAVE program for more details of the
103 integrated workflow).

104 Here we present a computational heuristic developed for early detection of SARS-CoV-2
105 emerging variants of interest, which combines spatiotemporal sequence prevalence dynamics
106 and geographic spread with functional impact prediction, that can be used to rank variants
107 composed of constellations of substitutions. The methods described have been used to rank
108 emerging variants of interest for the NIAID SAVE consortium Early Detection group every month
109 since early 2021 to inform wet-lab experimentation.

110

111

112 **Methodology and Results**

113 **Algorithms for Early Detection**

114 *Sequence Prevalence Dynamics* - The BV-BRC team has developed the *SARS-CoV-2 Early*
115 *Detection and Analysis Pipeline* to offer informatics support for analyzing emerging SARS-CoV-
116 2 variants from genomic sequencing data and associated epidemiological metadata processed
117 from public databases. Throughout the pandemic, the team has run this pipeline nearly every
118 week to process SARS-CoV-2 genomic sequencing and epidemiological data and support the
119 Early Detection component of the NIAID SAVE program. Data for this pipeline can be
120 downloaded from the EpiCov portal of GISAID²⁰, NCBI GenBank, Virus Pathogen Resource²³,

121 or BV-BRC²⁴ databases. A primary aspect of this pipeline is the ability to capture four sequence
122 prevalence dynamics segregated by month and geographic location: 1) the total SARS-CoV-2
123 genome sequence counts, 2) the genome sequence counts for specific lineages and variants, 3)
124 the sequence prevalence of these lineages and variants, and 4) the growth rates of these
125 lineages and variants from month to month (see **Supplementary Material** for more details).
126 These sequence prevalence dynamics are calculated for individual PANGO lineages²¹, single
127 amino acid substitutions found in any SARS-CoV-2 protein, and unique constellations of protein
128 substitutions denoted as “covariates”, which we refer to collectively as “variants”. Note that
129 covariates consist of a string of single amino acid mutations identified in one or more proteins of
130 some SARS-CoV-2 sequence isolate. Each covariate also belongs to a specific PANGO
131 lineage based on the nomenclature status of the origin sequence. Multiple covariates of a
132 single protein can belong to the same PANGO lineage. In this work, we focus on the analysis of
133 Spike covariates since this has been the initial focus of the NIAID SAVE program.

134 Generating the sequence prevalence dynamics of emerging variants provides the required
135 epidemiological parameters needed by the scoring heuristics for predicting which variants might
136 be of concern. We designed a workflow to capture these dynamics as an upstream component
137 of the scoring heuristics.

138 *Capturing the Dynamics of Emerging Variants* - A custom built pipeline was routinely used to
139 compute sequence prevalence dynamics by capturing SARS-CoV-2 variants and isolation
140 metadata (geographic location and date of isolation) from the genomic sequencing databases.
141 Strict quality control criteria were used to filter out genomes with high numbers of ambiguous or
142 indeterminate bases (n>x), low sequence length coverage (n<x,000kb), missing viral names, or
143 improper metadata such as incorrect representation of dates or region names. Genomes were
144 then pairwise aligned to the Wuhan-Hu-1 reference genome (NC_045512.2), and a constellation
145 of variants was extracted for the Spike protein, or for the entire SARS-CoV-2 proteome (all 16
146 non-structural proteins as well as E, M, N, S, ORF3a, ORF6, ORF7a, ORF7b, ORF8, ORF9b,
147 ORF10, and ORF14). Variant constellations can then be partitioned into temporal and
148 geographic groups. The total number of genomes isolated for these groups is also calculated
149 and serves as the denominator for the prevalence ratio (formula 1). Dates were then partitioned
150 by month, and variant constellation counts and total isolate counts per region per date month
151 were used to compute epidemiological dynamics, namely the prevalence and growth rates of
152 variants by month as shown in formulas (1) and (2).

153

$$(1) \text{ Prevalence Ratio} = \frac{\# \text{ Variant Sequences in Region } R \text{ during Period } P}{\# \text{ Total Sequences Isolated in Region } R \text{ during Period } P}$$

154

155

$$(2) \text{ Growth Rate} = \frac{\text{Prevalence Ratio in Region } R \text{ during Period } P}{\text{Prevalence Ratio in Region } R \text{ during Period } P-1}$$

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

Running this process to identify variant constellations and acquire region-date counts directly from the raw sequence data is a very computationally expensive task for a large batch of genomes and requires High-Performance Computing. An alternative approach is to use preprocessed data provided in GISAID metadata files, which can be downloaded with a registered GISAID account. Records include variant constellations, geographic location, date of collection, and basic quality control data such as the sequence length and ambiguous nucleotide content. These files can be used to extract the Spike variant constellation of each record, count the occurrence of these Spike variants by region and date, bin the dates by month, and compute the monthly prevalence and growth rate dynamics for each Spike variant based on the total sequence record counts per region and date. PANGO lineage designations can also be used to count the occurrence of specific lineages by region and date and compute spatiotemporal dynamics. A similar strategy can be used to collect data for single amino acid substitutions rather than variant constellations or PANGO Lineages, iterating through each sequence record, and counting the occurrence of each single mutation by region and date and then computing the prevalence and growth rates of these single mutations by month per region. This workflow was used to generate sequence prevalence dynamics based on either GISAID metadata files or GenBank/BV-BRC FASTA files and then fed into the scoring heuristics component of the pipeline (see the **Supplementary Material** for more details).

Sequence Prevalence Score - To identify SARS-CoV-2 variations with concerning epidemiological dynamics, a scoring heuristic based on sequence prevalence ratio (Formula 1), growth in sequence prevalence (Formula 2), and geographic spread was devised - the Sequence Prevalence Score. This scoring method can be applied to rank variants within the entire dataset, within a specific PANGO lineage, a specific WHO clade, or a user supplied list of covariates. First, this method segregates variants for each country. Next, only variants with a sequence count greater than 10 in the most recent month are retained to control for large apparent growth rates associated with small numbers. Any variants that were filtered out are assigned a score of 0. To calculate the Sequence Prevalence Score, the most recent three months of data are used. A score of 1 is assigned for every country/month combination in which the sequence prevalence is >5% or the growth rate from the previous month is >5-fold. These numbers are then summed to obtain the final Sequence Prevalence Score across all countries/month combinations. Three months of data is the default interval applied, but users

187 can specify this parameter through a "--interval" argument. **Figure 1** shows a ranking using the
188 *Sequence Prevalence Score* to prioritize variants from GISAID data processed in November of
189 2021, which is considered the initial month of emergence of the Omicron variant. In this
190 ranking, the *Sequence Prevalence Score* for the Omicron variant is still relatively small but
191 detectable.

192 *Functional Impact Score* – While the *Sequence Prevalence Score* quantifies prevalence
193 properties of variants, it requires some minimum time period to observe concerning trends and
194 may not rank concerning variants high at early stages of emergence. A complementary
195 approach for analyzing emerging variants independent of epidemiological dynamics is to predict
196 their functional impact using prior knowledge from experimental datasets. We have designated
197 regions of the Spike protein that have been experimentally shown to impact immune escape,
198 receptor binding affinity, or viral replication as "Sequence Features of Concern" (SFoC). We
199 detail our procedure for selecting SFoCs in the following section, but overall, these SFoCs
200 include sites that could impact the binding of one or more monoclonal antibody classes¹⁰,
201 neutralization with infection or vaccine (mrna-1273) induced antibodies, affect receptor binding
202 affinity, or functionally important sites (NTD Supersite¹³, Furin Cleavage Site^{28,29}, or D614G¹⁶).

203 Upon establishing our list of SFoCs, we assign each Spike variant a *Functional Impact Score*
204 based on positional overlap with these critical regions. For each mutated position in the variant,
205 if an overlap is found with one of the regions in the SFoC list, a score of 1 is assigned treating
206 separately each of the monoclonal antibody classes, convalescent serum, vaccine serum, ACE2
207 binding affinity, NTD supersite, furin cleavage site, and site D614G. Any amino acid substitution
208 or deletion that has a position falling within an SFoC is treated as one scorable mutation.

209 Summing all the scores of each position mutated in the variant produces the *Functional Impact*
210 *Score*. In **Figure 2** we provide a visual representation of what this positional overlap with SFoCs
211 defined by deep mutational scanning antibody escape data would look like. The figure comes
212 from an implementation of these annotations in the genome browser of the *BV-BRC SARS-*
213 *CoV-2 Variant Tracker*²⁴ and quantifies impact of monoclonal antibody binding by class for a
214 mutation at each site on the Receptor Binding Domain.

215 *Sequence Features of Concern* – Most of the data used to define the SFoCs were derived from
216 the deep mutational scanning experiments conducted by the Bloom Lab^{2,3,4,5,6,7,8,9}. The resulting
217 experimental data quantified the mutation impact towards monoclonal antibody escape,
218 convalescent serum antibody escape, vaccine (mrna-1273) elicited antibody escape, and ACE2
219 binding affinity for nearly every position on the Receptor Binding Domain (RBD). To achieve

220 these quantifications, the Bloom Lab constructed an RBD mutant library such that each amino
221 acid site on the RBD was mutated with the 19 possible amino acid substitutions in the genetic
222 background of the Wuhan-Hu-1 reference strain. The Bloom Lab used rigorous statistical
223 processing to calculate an “escape fraction” for antibody escape (all between 0 and 1) and
224 “binding average” for ACE2 affinity (all between -5 and 1) for every mutation at every position of
225 the RBD. Each of the different monoclonal antibodies belonging to one of the four Barnes et al.
226 structural epitope classes¹⁰, subject specific convalescent sera, and subject specific vaccine
227 sera had their own escape fraction scores per mutation per site. The data from all these deep
228 mutational scanning studies can be downloaded and explored at
229 https://jbloomlab.github.io/SARS2_RBD_Ab_escape_maps/.

230 We examined the distribution of scores for each antibody escape datasets and the ACE2
231 binding dataset to narrow down on positions of the RBD vulnerable to significant increase in
232 antibody escape or ACE2 binding affinity upon mutation. With a consolidated violin plot for all
233 monoclonal antibodies and convalescent/vaccine sera, the analysis of antibody escape data
234 showed that most of the escape fraction values were close to the 0 baseline and less than 0.2
235 (**Figure 3**). Therefore, to capture positions on the RBD that lead to strong antibody escape
236 upon being mutated, an escape fraction threshold of 0.25 was applied. Consequentially, the
237 antibody escape SFoCs were defined as RBD sites with one or more mutations that lead to an
238 escape fraction exceeding this threshold for some monoclonal antibody, convalescent subject
239 sera, or vaccine subject sera. The monoclonal antibodies corresponding to a mutation
240 exceeding this escape fraction threshold were categorized into their structural epitope class to
241 generalize the scoring for functional impact. As a result of this threshold, we designated 75 sites
242 on the RBD that could significantly impact the binding of up to four antibody classes and 36
243 sites that could significantly impact the binding of antibodies from convalescent or vaccine sera.

244 Similarly, we evaluated the distribution of scores for the ACE2 binding affinity dataset. This
245 analysis showed that most scores were close to the 0 baseline or negative, where a negative
246 score implied a decrease in binding affinity (**Figure 4**). To identify mutations that led to
247 increased ACE2 binding affinity, a binding average threshold of 0.1 was selected. As a result,
248 each site with one or more mutations that exceeded this threshold was defined as an SFoC for
249 increased ACE2 affinity, thus designating 12 sites that could significantly increase the binding to
250 ACE2 upon mutation. We found site 501 to be included in this list, which is a notable site that
251 leads to high degree of conformational alterations of the Spike RBD when bound to ACE2 upon
252 acquiring a mutation³⁹.

253 The remaining Sequence Features of Concern were those deemed critical for adaptive immunity
254 or viral tropism, such as the NTD supersites¹³ (sites 14-20, 140-158, 245-264), site 614 of the
255 Spike¹⁶, and the region flanking the furin cleavage site^{28,29} (sites 671-692). These were
256 determined through literature curation.

257 Composite Score - Once the *Sequence Prevalence Score* and the *Functional Impact Score*
258 have been computed, the two are summed to produce the *Composite Score*, which is used in
259 our monthly reports to NIAID SAVE for variant rankings. *Composite Scoring* can be applied to
260 all variants in a dataset, variants among a specified WHO clade, covariates among a specified
261 PANGO lineage, or variants in a user supplied list. Thus, the *Composite Score* can
262 simultaneously identify variants with alarming sequence prevalence dynamics **and** variants that
263 would be predicted to impact important functional characteristics of the virus **or** both. For
264 example, an initial analysis of the Omicron variant using epidemiological data from November
265 2021 did not show a high *Sequence Prevalence Score* (**Figure 1**), but the original Omicron
266 sequence did show a very high *Functional Impact Score* and therefore a high *Composite Score*
267 (**Figure 5**). These results highlight the importance of paying attention to both the *Sequence*
268 *Prevalence Score* and *Functional Impact Score* for the early identification of Variants of Interest
269 for further evaluation.

270 The *Composite Score* is also very useful in quantifying subtle differences among covariates of
271 the same clade. By January 2022, the most dominant lineage of Omicron clade was BA.1,
272 which included several sub-lineages with varying Spike covariates, most significantly the
273 addition of the R346K mutation. At the same time, BA.2 was also emerging and there was a
274 primary variant constellation similar to BA.1 but with several unique mutation sites. When a list
275 of these distinct Omicron covariates was supplied to the ranking algorithm, differences between
276 the original BA.1 covariate and BA.1 + R346K could be observed through an increase in the
277 functional impact score (**Figure 6**). In contrast, many of the other covariates had a *Sequence*
278 *Prevalence Score* of 0, which indicated that those covariates were not displaying any significant
279 regional growth and likely not as threatening as the original BA.1 or the BA.1 + R346K (now
280 known as BA.1.1) covariates.

281 Mutation Prevalence Score – In addition to the covariate constellation analysis, a *Mutation*
282 *Prevalence Score* analyzing single amino acid substitutions on the SARS-CoV-2 Spike protein
283 is also calculated. As with the *Sequence Prevalence Score*, this approach uses data from the
284 past three months to assign a score of 1 for every country/month combination in which the
285 prevalence of an amino acid mutation is >5% or the growth rate is greater than 5-fold. **Figure**

286 **7A-B** show the results of ranking mutations within the RBD and NTD using global GISAID
287 sequence data from December 2021.

288 *Emerging Lineage Score* – In some cases, researchers may just want to know how the various
289 PANGO Lineage designations differ in terms of their epidemiological dynamics. As we saw with
290 Delta, there were a multitude of AY.* lineages for the entire WHO clade designated in a
291 relatively short time frame, so ranking these lineages would be helpful to identify which should
292 be prioritized for further analysis.

293 As with the *Sequence Prevalence Score*, the *Emerging Lineage Score* begins by filtering for
294 covariates with an assigned country and with a variant count greater than 10 in the most recent
295 month. From there, using the past three months of data, for each PANGO lineage, every
296 unique covariant/country/month combination in which the growth rate is greater than 15 is
297 assigned a score of 1; these values are summed to compute the *Emerging Lineage Score*.
298 Since this algorithm is counting multiple distinct covariates comprising each lineage, it could be
299 biased towards PANGO lineages with very abundant covariates; hence, we used a higher
300 growth rate threshold to capture the key covariates driving the overall growth of the lineage. A
301 growth rate of 15 was chosen as it results in a relatively stable list of PANGO lineages. Growth
302 rates above 15 did not significantly affect the ranking of the list. This growth rate is also
303 appealing in that it is relatively high and therefore relatively stringent. **Figure 8A-B** shows the
304 results from this method using GISAID data from December 2021 and January 2022 to rank
305 lineages globally. BA.1 was the dominant Omicron lineage in December 2021 and was the
306 lineage with the highest *Emerging Lineage Score*. (**Figure 8A**). However, by January 2022
307 additional Omicron lineages were rapidly growing with the presence of BA.1.1 and BA.2 (**Figure**
308 **8B**). Since these lineages are made up of multiple covariates, we could take the results
309 returned from the *Emerging Lineage Score* to decide which covariates within these lineages
310 warranted further investigation by running a PANGO lineage specific *Composite Score* ranking
311 to prioritize the covariates within a specific lineage, as shown in **Figure 9** with BA.2, which
312 captured a single covariate of the lineage with the strongest dynamics as early as January
313 2022.

314

315 **Visualizing Early Detection**

316 To complement our early detection analysis of emerging SARS-CoV-2 variants through our
317 scoring and ranking algorithms, we found it useful to visualize variant growth both globally and

318 regionally to further understand the dynamics of these variants and facilitate early detection.
319 We demonstrate the utility of these visualizations for early detection purposes by providing
320 some case studies regarding the early dynamics of the Delta and Omicron variants.

321 Visualizing Relative Growth of PANGO Lineages – When a new variant displays alarming
322 epidemiological dynamics or predicted functional changes, like Delta and Omicron did,
323 researchers may want to visualize the growth dynamics of the new variant in the context of how
324 the prevalence of other variants are changing. We commonly see during viral evolution that
325 when a new dominant variant/strain emerges, it triggers a phenomenon where the growth of the
326 currently circulating variants suddenly begin to sharply decline, perhaps because the new
327 variant has a fitness advantage and is able to outcompete the older variants^{16,19,31,33}. If we
328 observe that the prevalence of a novel variant with alarming characteristics is increasing with a
329 corresponding sudden decline in growth of other circulating variants, this will further indicate the
330 early detection of a potential Variant of Concern. As an example, prior to the emergence of
331 Delta, B.1.1.7-derived Alpha variants were the most dominantly circulating variants around the
332 world. However, between May and June of 2021, it was becoming clear that the newly
333 emerging Delta variant was displaying noteworthy properties¹⁹ and very quickly replacing the
334 other circulating variants, including B.1.1.7 (Alpha), both globally (**Figure 10A**) and regionally,
335 especially in the UK (**Figure 10B**). By visualizing these dynamics in stacked line plots, the
336 relative magnitude by which a novel variant is growing offers further evidence of the early
337 detection of a potential Variant of Concern.

338 Visualizing Growth of Variants – In addition to tracking the emergence and growth of new
339 PANGO lineages, it is also useful to visualize the evolution and growth of variants within the
340 lineage. As discussed earlier, B.1.1.529 (Omicron) started to show rapid growth in December
341 2021 and then quickly accumulated additional substitutions, ultimately generating the newly
342 designated BA.1 and BA.2 lineages and sub-lineages. By providing a list of covariates of
343 interest, like the one used in **Figure 6**, our pipelines produced a graph showing the prevalence
344 of a selected list (**Figure 11**). Comparing the *Composite Score* results from **Figure 6** with the
345 visualization in **Figure 11**, some interesting insights about BA.1 + R346K emerge. BA.1 +
346 R346K had a high functional impact score, and while the *Sequence Prevalence Score* was also
347 high, it wasn't quite as high as BA.1 for the month of January 2022. However, the **Figure 11**
348 visualization shows that BA.1 + R346K was exhibiting a sharper change in its global prevalence
349 relative to BA.1, suggesting that this variant would warrant further monitoring. Indeed, these

350 plots provide a complementary representation to the *Composite Score* ranking to facilitate early
351 detection analysis and more confidently identify variants that warrant experimental evaluation.

352 *Visualizing Growth of Individual Amino Acid Substitutions* – Analysis of the characteristics of
353 lineages and covariates also provided some insights into the different amino acid mutations that
354 contribute to the multitude of covariates, in some cases from different lineages, perhaps due to
355 convergent evolution or recombination. To assess their individual effects, the dynamics of
356 selected single amino acid substitutions can also be plotted. For example, prior to January
357 2022, the L24-, R346K, N440K, G446S, L452R, A701V mutations were appearing sporadically
358 throughout our ranked covariates. Plotting the dynamics of these individual amino acid
359 mutations over subsequent time periods shows that the R346K and G446S mutations started to
360 decrease in prevalence at the same time as the prevalence of L24- was rapidly increasing,
361 suggesting that viruses carrying this mutation may possess a fitness advantage (**Figure 12**).
362 Indeed, this L24- is part of an extended deletion that distinguishes BA.2, which subsequently
363 replaced BA.1.

364

365

366 **Challenges**

367 Defining SARS-CoV-2 variants that warrant experimental evaluation for functional testing
368 presents significant challenges. Early genomic sequencing data is often subject to data
369 imbalances or biases with respect to specific geographic regions. Wealthier countries with
370 higher sequencing capacity, such as the US and UK, are responsible for the majority of publicly
371 deposited SARS-CoV-2 genomes. Of the 4.5 million SARS-CoV-2 genomes available in
372 GenBank and BV-BRC as of April 2022, roughly 47% were from the US and 38% from the UK.
373 Another challenge is the sequence ambiguity that can occur as a new variant emerges and
374 before the sequencing assays can be optimized. And since the SARS-CoV-2 genomes
375 submitted to the public databases have already been assembled, the quality of the read level
376 data cannot be easily evaluated independently. Processing variant data through the GISAID
377 metadata file downloads, many sequences appeared to have reverted to ancestral residues in
378 comparison to the original Omicron outbreak sequences, but in many cases this is due to low
379 sequence coverage in certain genomic regions that is not apparent in the metadata file. Indeed,
380 processing assembled GenBank sequencing data from BV-BRC, only about 25% of sequences
381 had little to no ambiguities, and the amount of ambiguity in the sequencing data fluctuated

382 during the initial emergence of certain important variants, like Delta and Omicron, making it
383 challenging to compute true sequence prevalence of authentic covariates. Another challenge is
384 choosing the amount of data that ought to be regularly downloaded for computing the early
385 detection scoring heuristics. While focusing on the most recent data could potentially be used
386 to identify concerning variants more swiftly, a potential drawback would be sequence biases
387 resulting in minimal representation. On the other hand, longer temporal data is more
388 comprehensive and accurate, but could delay identification of newly emerging variants of
389 concern. In our pipeline, we allow the option to choose anywhere from the past 2 – 6 months of
390 global sequencing data to evaluate, with a default of 3 as our best attempt to set a balance
391 between early detection and unbiased, accurate results. Finally, the most enduring challenge is
392 the fact that these data are very large and continuously growing, as new SARS-CoV-2
393 sequencing data are being deposited by the thousands every day. Designing pipelines to
394 carryout real-time genomics analysis for a sheer amount of data is a technically challenging
395 task, and our techniques on how best to manage, analyze, and scale will need to continuously
396 adapt.

397

398

399 **Discussion**

400 Over two and a half years since the initial declaration of the COVID-19 pandemic, it seems clear
401 that SARS-CoV-2 will persist in our community and remain a public health issue for the
402 indefinite future. However, if we, as a biomedical community, come together and maximize our
403 resources to combat this virus, we can consistently minimize the threat it brings to our world and
404 transition to a phase in which SARS-CoV-2 becomes an endemic infection with only modest
405 effects on public health. A major factor that could contribute to consistently minimizing the
406 threat brought by SARS-CoV-2, or any other emerging pathogen, is through genomic
407 surveillance. Our most precise approach to monitoring viral evolution to ensure that we
408 maintain reliable therapeutics and accurate diagnostics is by routinely collecting samples from
409 infected individuals and using sequencing technologies to acquire the whole genome
410 sequences. With the COVID-19 outbreak, the research and public health communities have
411 truly excelled at this task, as we have now reached a point where millions of SARS-CoV-2
412 genome sequences have been deposited in public databases. That being said, all of these data
413 are only as powerful as the computational resources used to analyze them. Thus, this

414 explosion in publicly available viral genomes also calls for the development of appropriate
415 computational frameworks that can process and scale as the data grows to enable the timely
416 identification and prioritization of emerging variants.

417 In this work, we present approaches to process SARS-CoV-2 genomic sequences along with
418 epidemiological metadata on a regular basis and apply scoring heuristics to prioritize variants
419 based on their epidemiological dynamics and predicted functional characteristics by computing
420 *Sequence Prevalence*, *Functional Impact*, and the *Composite Scores*. The output provides
421 concise lists of ranked variant constellations (covariates), offering a straightforward approach for
422 wet-lab scientists to immediately determine which combinations of mutations ought to be
423 evaluated experimentally. These methods were validated through the detection of the Omicron
424 variant and provided a relatively high-ranking score at early stages of emergence in November
425 2021. In addition to early detection of novel variants like Omicron, our system makes it easy to
426 evaluate the subtle differences among the multitude of covariates arising from a single lineage,
427 like comparing the BA.1 + R346K covariate to the original BA.1 covariate. Finally, we also
428 provide multiple visualization methods for variant growth either by PANGO lineage, covariate, or
429 single amino acid substitution and demonstrate how coupling rankings with visualizations can
430 further ground our confidence in early detection of variants that warrant experimental evaluation.

431 While the initial focus of this work was on Spike protein variants, as that was NIAID SAVE's
432 interest for evaluation, the framework was recently extended to score and rank proteome-wide
433 SARS-CoV-2 variant constellations and single amino acid substitutions, which we provide in our
434 publicly available pipeline. While the primary focus was the Spike protein due to its critical role
435 in adaptive immunity and viral tropism, the community is beginning to take serious interest in
436 mutations arising in non-structural proteins, particularly nsp3, nsp5, and RNA-dependent RNA
437 Polymerase (nsp12), due to their importance in the SARS-CoV-2 replication cycle and antiviral
438 drug targeting^{34,35,36,37,38}. We are paying close attention to the literature to monitor the science
439 behind non-Spike protein regions that play key roles in replication or impact drug targeting, and
440 are continually updating our Sequence Features of Concern to account for this new knowledge.
441 Ultimately, our framework can begin providing *Composite Scores* for a variant constellation
442 specific to any SARS-CoV-2 protein.

443 The methods presented in this work could be extended for evaluating variants of other viral
444 species if sufficient data granularity is available. This approach requires enough genomic
445 sequencing data, consistent spatiotemporal isolation metadata, a methodology to compute
446 variants with respect to a reference or a consensus genome²², and sufficient prior knowledge

447 through experimental data to define Sequence Features of Concern and quantify functional
448 impacts. Moreover, these algorithms could be extended to evaluate genomic surveillance data
449 from zoonotic disease reservoirs, such as influenza virus in avian or swine species. Indeed,
450 several projects already exist to collect viral genomic sequences from such reservoirs and
451 warehouse these data in public databases¹⁸. Overall, the methodologies described here can
452 play an important role in a complete public health ecosystem by utilizing genomic sequencing
453 data to monitor viral evolution and remain steps ahead of SARS-CoV-2, or any other virus, and
454 ultimately deter the next pandemic.

455

456

457 **Data Availability Statement**

458 Publicly available datasets were analyzed in this work, and the original contributions presented
459 are included in the article/**Supplementary Material**. Further inquiries can be directed to the
460 corresponding author.

461

462

463 **Conflict of Interest**

464 The authors declare that the research was conducted in the absence of any commercial or
465 financial relationships that could be construed as a potential conflict of interest.

466

467

468 **Author Contributions**

469 ZSW conceptualized the methods, collected/analyzed data, developed the public version of the
470 pipeline, and wrote the original draft of the manuscript. JD, RDO, RS, and MS conceptualized
471 the methods and contributed to pipeline development. AN, YZ and CMZ conceptualized the
472 methods and reviewed and edited the manuscript. RHS was the principal investigator who
473 conceived the project, conceptualized the methods, supervised the project, acquired funding,
474 and reviewed and edited the manuscript.

475

476

477 **Funding**

478 This work has been funded with Federal funds from the National Institute of Allergy and
479 Infectious Diseases, National Institutes of Health, Department of Health and Human
480 Services - [HHS75N93019C00076](#).

481

482

483 **Acknowledgements**

484 We acknowledge the Bloom Lab at Fred Hutchinson Cancer Research Center for their advice
485 and data sharing, the Korber Lab at Los Alamos National Laboratory for their advice on
486 methodology, Fritz Orbermeyer/Lemieux Lab at the Broad Institute for code sharing, the San
487 Diego Supercomputer Center/XSEDE for the allocation of the Expanse compute resources, and
488 both the originating and submitting laboratories for the sequence data deposited in INSDC and
489 GISAID databases. The project has benefited from the ongoing discussion among the
490 computational biologists and experimentalists in the NIAID SAVE consortium and among the
491 analysts and developers of the BV-BRC.

492

493

494 **Supplementary Material**

495 The *BV-BRC SARS-CoV-2 Early Detection and Analysis Pipeline*, the list of Sequence Features
496 of Concern, and a more detailed version of the algorithms along with pseudocode are available
497 from https://github.com/zw Wallace425/SARS-CoV-2_Pipeline.

498

499

500

501

502

503

504

505 References

- 506 (1) DeGrace, M.M et al. Defining the risk of SARS-CoV-2 variants on immune protection.
507 *Nature*. 2022. <https://doi.org/10.1038/s41586-022-04690-5>
- 508 (2) Dong, J., Zost, S.J., Greaney, A.J. *et al.* Genetic and structural basis for SARS-CoV-2
509 variant neutralization by a two-antibody cocktail. *Nat Microbiol* 6, 1233–1244 (2021).
510 <https://doi.org/10.1038/s41564-021-00972-2>
- 511 (3) Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, *et al.* Complete Mapping of Mutations
512 to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition,
513 *Cell Host & Microbe*, Volume 2, Issue 1, 2021, Pages 44-57.e9, ISSN 1931-3128.
514 <https://doi.org/10.1016/j.chom.2020.11.007>
- 515 (4) Greaney, A.J., Starr, T.N., Barnes, C.O. *et al.* Mapping mutations to the SARS-CoV-2
516 RBD that escape binding by different classes of antibodies. *Nat Commun* 12, 4196
517 (2021). <https://doi.org/10.1038/s41467-021-24435-8>
- 518 (5) Allison J. Greaney, Andrea N. Loe, Lauren E. Gentle, *et al.* Antibodies elicited by mRNA-
519 1273 vaccination bind more broadly to the receptor binding domain than do those from
520 SARS-CoV-2 infection. 2021. *Science Translational Medicine*, 13, 60.
521 <https://www.science.org/doi/abs/10.1126/scitranslmed.abi9915>
- 522 (6) Tyler N. Starr, Allison J. Greaney, Adam S. Dingens, Jesse D. Bloom. Complete map of
523 SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its
524 cocktail with LY-CoV016. *Cell Reports Medicine*. Volume 2, Issue 4. 2021. 100255.
525 ISSN 2666-3791. <https://doi.org/10.1016/j.xcrm.2021.100255>
- 526 (7) Starr, T.N., Czudnochowski, N., Liu, Z. *et al.* SARS-CoV-2 RBD antibodies that
527 maximize breadth and resistance to escape. *Nature* 597, 97–102 (2021).
528 <https://doi.org/10.1038/s41586-021-03807-6>
- 529 (8) Tyler N. Starr, Allison J. Greaney, Amin Addetia, *et al.* Prospective mapping of viral
530 mutations that escape antibodies used to treat COVID-19. 2021. *Science*, 850-854, 371,
531 6531. <https://www.science.org/doi/abs/10.1126/science.abf9302>
- 532 (9) Tortorici, M.A., Czudnochowski, N., Starr, T.N. *et al.* Broad sarbecovirus neutralization
533 by a human monoclonal antibody. *Nature* 597, 103–108 (2021).
534 <https://doi.org/10.1038/s41586-021-03817-4>
- 535 (10) Barnes, C.O., Jette, C.A., Abernathy, M.E. *et al.* SARS-CoV-2 neutralizing
536 antibody structures inform therapeutic strategies. *Nature* 588, 682–687 (2020).
537 <https://doi.org/10.1038/s41586-020-2852-1>

- 538 (11) Matteo Chiara, Anna Maria D'Erchia, Carmela Gissi, *et al.*, Next generation
539 sequencing of SARS-CoV-2 genomes: challenges, applications and
540 opportunities, *Briefings in Bioinformatics*, Volume 22, Issue 2, March 2021, Pages 616–
541 630. <https://doi.org/10.1093/bib/bbaa297>
- 542 (12) Deng, X., Achari, A., Federman, S. *et al.* Metagenomic sequencing with spiked
543 primer enrichment for viral diagnostics and genomic surveillance. *Nat Microbiol* 5, 443–
544 454 (2020). <https://doi.org/10.1038/s41564-019-0637-9>
- 545 (13) Matthew McCallum, Anna De Marco, Florian A. Lempp, *et al.*, N-terminal domain
546 antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *Cell*, Volume 184,
547 Issue 9, 2021, Pages 2332-2347.e16, ISSN 0092-8674.
548 <https://doi.org/10.1016/j.cell.2021.03.028>
- 549 (14) Benjamin L. Sievers, Saborni Chakraborty, Yong Xue, *et al.* Antibodies elicited by
550 SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against
551 Beta and Omicron pseudoviruses. 2022. *Science Translational Medicine*, eabn7842, 14.
552 634, <https://www.science.org/doi/abs/10.1126/scitranslmed>
- 553 (15) Obermeyer, Fritz, Jankowiak, Martin, Barkas, Nikolaos, *et al.*, Analysis of 6.4
554 million SARS-CoV-2 genomes identifies mutations associated with fitness. medRxiv.
555 2022. <https://doi.org/10.1101/2021.09.07.21263228>
- 556 (16) Korber B, Fischer WM, Gnanakaran S, *et al.* Tracking Changes in SARS-CoV-2
557 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. *Cell*. 2020 Aug
558 20;182(4):812-827.e19. Epub 2020 Jul 3. PMID: 32697968; PMCID: PMC7332439.
559 <https://doi.org/10.1016/j.cell.2020.06.043>
- 560 (17) Maher MC, Bartha I, Weaver S, di Iulio J, Ferri E, Soriaga L, *et al.* Predicting the
561 mutational drivers of future SARS-CoV-2 variants of concern. *Sci Transl Med*. 2022 Feb
562 23;14(633):eabk3445. Epub 2022 Feb 23. PMID: 35014856; PMCID: PMC8939770.
563 <https://doi.org/10.1126/scitranslmed.abk3445>
- 564 (18) Tavis K Anderson, Blake Inderski, Diego G Diel, *et al.* The United States Swine
565 Pathogen Database: integrating veterinary diagnostic laboratory sequence data to
566 monitor emerging pathogens of swine, *Database*, Volume 2021, 2021,
567 baab078. <https://doi.org/10.1093/database/baab078>
- 568 (19) McCrone JT, Hill V, Bajaj S, *et al.* Context-specific emergence and growth of the
569 SARS-CoV-2 Delta variant. medRxiv [Preprint]. 2021 Dec 21:2021.12.14.21267606.
570 PMID: 34981069; PMCID: PMC8722612. <https://doi.org/10.1101/2021.12.14.21267606>

- 571 (20) Khare, S., et al (2021) GISAID's Role in Pandemic Response. *China CDC*
572 *Weekly*, 3(49): 1049-1051. PMID: 8668406. <https://doi.org/10.46234/ccdcw2021.255>
- 573 (21) Rambaut, A., Holmes, E.C., O'Toole, Á. *et al.* A dynamic nomenclature proposal
574 for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat Microbiol* 5, 1403–1407
575 (2020). <https://doi.org/10.1038/s41564-020-0770-5>
- 576 (22) Zhang Y, Aevermann BD, Anderson TK, *et al.* Influenza Research Database: An
577 integrated bioinformatics resource for influenza virus research. *Nucleic Acids Res.* 2017
578 Jan 4;45(D1):D466-D474. Epub 2016 Sep 26. PMID: 27679478; PMCID: PMC5210613.
579 <https://doi.org/10.1093/nar/gkw857>
- 580 (23) Pickett BE, Sadat EL, Zhang Y, et al. ViPR: an open bioinformatics database and
581 analysis resource for virology research. *Nucleic Acids Res.* 2012;40(Database
582 issue):D593-D598. <https://doi.org/10.1093/nar/gkr859>
- 583 (24) The Bacterial and Viral Bioinformatics Resource Center (BV-
584 BRC). <https://www.bv-brc.org/>
- 585 (25) Derek W Wright, William T Harvey, Joseph Hughes, *et al.* Tracking SARS-CoV-2
586 mutations and variants through the COG-UK-Mutation Explorer, *Virus Evolution*, Volume
587 8, Issue 1, 2022, veac023. <https://doi.org/10.1093/ve/veac023>
- 588 (26) Harvey, W.T., Carabelli, A.M., Jackson, B. *et al.* SARS-CoV-2 variants, spike
589 mutations and immune escape. *Nat Rev Microbiol* 19, 409–424 (2021).
590 <https://doi.org/10.1038/s41579-021-00573-0>
- 591 (27) Centers for Disease Control and Prevention, SARS-CoV-2 Variants of Concern;
592 [www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-](http://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
593 [info.html](http://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
- 594 (28) Escalera, A. et al. Mutations in SARS-CoV-2 variants of concern link to increased
595 spike cleavage and virus transmission. *Cell Host Microbe.* 2022. 30, 373–387.e7.
596 <https://doi.org/10.1016/j.chom.2022.01.006>
- 597 (29) Liu, Y. et al. Delta spike P681R mutation enhances SARS-CoV-2 fitness over
598 Alpha variant. Preprint at bioRxiv. 2021. <https://doi.org/10.1101/2021.08.12.456173>
- 599 (30) Planas, D., Saunders, N., Maes, P. *et al.* Considerable escape of SARS-CoV-2
600 Omicron to antibody neutralization. *Nature* 602, 671–675 (2022).
601 <https://doi.org/10.1038/s41586-021-04389-z>
- 602 (31) Martin DP, Weaver S, Tegally H *et al.* The emergence and ongoing convergent
603 evolution of the SARS-CoV-2 N501Y lineages. *Cell.* 2021 Sep 30;184(20):5189-5200.e7.

- 604 Epub 2021 Sep 7. PMID: 34537136; PMCID: PMC8421097.
605 <https://doi.org/10.1016/j.cell.2021.09.003>
- 606 (32) Starr TN, Greaney AJ, Hilton SK, *et al.* Deep Mutational Scanning of SARS-CoV-
607 2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding. *Cell*.
608 2020 Sep 3;182(5):1295-1310.e20. Epub 2020 Aug 11. PMID: 32841599; PMCID:
609 PMC7418704. <https://doi.org/10.1016/j.cell.2020.08.012>
- 610 (33) Bin Zhou, Tran Thi Nhu Thao, Donata Hoffmann, *et al.* SARS-CoV-2 spike
611 D614G change enhances replication and transmission. *Nature*, 2021.
612 <https://doi.org/10.1038/s41586-021-03361-1>
- 613 (34) Yuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, *et al.*
614 Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in Vitro
615 bioRxiv 2022.06.06.494921; doi: <https://doi.org/10.1101/2022.06.06.494921>
- 616 (35) Dirk Jochmans, Cheng Liu, Kim Donckers, *et al.* The substitutions L50F, E166A
617 and L167F in SARS-CoV-2 3CLpro are selected by a protease inhibitor *in vitro* and
618 confer resistance to nirmatrelvir bioRxiv 2022.06.07.495116.
619 <https://doi.org/10.1101/2022.06.07.495116>
- 620 (36) Martin Martinot, Aude Jary, Samira Fafi-Kremer, *et al.* Emerging RNA-Dependent
621 RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With
622 Protracted Coronavirus Disease 2019, *Clinical Infectious Diseases*, Volume 73, Issue 7,
623 1 October 2021, Pages e1762–e1765. <https://doi.org/10.1093/cid/ciaa1474>
- 624 (37) Szemiel AM, Merits A, Orton RJ, *et al.* (2021) *In vitro* selection of Remdesivir
625 resistance suggests evolutionary predictability of SARS-CoV-2. *PLOS Pathogens* 17(9):
626 e1009929. <https://doi.org/10.1371/journal.ppat.1009929>
- 627 (38) Tchesnokov EP, Gordon CJ, Woolner E, *et al.* Template-dependent inhibition of
628 coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second
629 mechanism of action. *J Biol Chem*. 2021 Aug;297(2):101048]. 2020;295(47):16156-
630 16165. <https://doi.org/10.1074/jbc.AC120.015720>
- 631 (39) Gupta R. SARS-CoV-2 Omicron spike mediated immune escape and tropism
632 shift. *Res Sq [Preprint]*. 2022 Jan 17. PMID: 35075452; PMCID: PMC8786230.
633 <https://doi.org/10.21203/rs.3.rs1191837/v1>
634

WHO Label	Variant	Sequence Prevalence Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5
Delta	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3
Omicron	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2

635

636

637

638


639

640

641

642

Figure 1 – Global Spike Variant Ranking with the *Sequence Prevalence Score*. The output of a ranking based on GISAID data up to November 2021. The analysis returns a global ranking for all Spike protein variants ranked by the *Sequence Prevalence Score*. The initial emergence of the Omicron variant is being captured in this ranking, but at a relatively low rank, as highlighted in the table.



643

644 **Figure 2 – Sequence Features of Concern from Deep Mutational Scanning Antibody**

645 **Escape Data.** An image from the *BV-BRC SARS-CoV-2 Variant Tracker*²⁴ genome browser
646 shows a heatmap that quantifies the median escape fraction for each antibody class (Class 1 –
647 4), with the darker blue indicating greater escape fraction, implying greater antibody escape due
648 to the mutation. We use these quantifications of potential antibody escape per mutated site per
649 antibody class to define one type of Sequence Features of Concern. By identifying overlap
650 between variants (bottom track) and these Sequence Features of Concern we can compute the
651 *Functional Impact Score*.

652

653

654

655

656


657

658

659

660

Distribution of Antibody and Serum Escape Fractions from Deep Mutational Scanning



661
662 **Figure 3 – Defining Sequence Features of Concern from a Threshold of Escape Fractions.**
663 Violin plots of the distribution of escape fraction scores for monoclonal antibody escape and
664 serum antibody escape from the Bloom Lab deep mutational scanning data. This distribution
665 analysis led to an escape fraction threshold cutoff of 0.25 and subsequently led to the
666 designation of 75 RBD sites significantly impacting monoclonal antibody binding and 36 sites
667 impacting convalescent/Moderna vaccine (mrna-1273) sera elicited antibodies upon mutation.
668
669
670
671
672
673
674


675

676

677

678

Distribution of ACE2 Binding Scores from Deep Mutational Scanning



679

680 **Figure 4 – Defining Sequence Features of Concern from a Threshold of ACE2 Binding**

681 **Scores.** The distribution of ACE2 binding average scores from the Bloom Lab deep mutational
682 scanning data. A score below 0 indicates a decrease in ACE2 binding affinity upon mutation,
683 whereas a score above 0 indicates an increase in ACE2 affinity. Subsequently, this distribution
684 analysis was used to select a threshold value of 0.1, that led to designating 12 RBD sites that
685 could significantly increase ACE2 binding affinity upon mutation.

686

687

WHO Label	Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161	10	171
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118	10	128
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98	9	107
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42	9	51
Omicron	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2	36	38
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22	10	32
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17	11	28
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13	7	20
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8	10	18
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8	10	18
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9	9	18
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8	10	18
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9	8	17
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5	11	16
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6	10	16
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6	10	16
Delta	LSF,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7	9	16
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5	10	15
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5	10	15
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6	9	15
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5	10	15
Delta	LSF,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5	10	15
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4	10	14
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4	10	14
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3	11	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4	10	14
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5	9	14
Delta	LSF,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4	10	14
Delta	LSF,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4	10	14
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	11	14
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3	11	14
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4	9	13
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4	9	13
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3	10	13
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3	10	13
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4	9	13
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3	10	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4	9	13
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	10	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3	9	12
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3	9	12
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3	9	12
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3	9	12
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4	7	11
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3	7	10
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3	5	8

688

689 **Figure 5 – Global Spike Variant Ranking with the Composite Score.** The output of a ranking
 690 based on GISAID data up to November 2021. The analysis returns a global ranking for all the
 691 Spike variants based on a Composite Score. In this case, the Omicron variant (highlighted in
 692 yellow) jumped considerably in rank relative to the Sequence Prevalence Score in Figure 1,
 693 thus showing the relevance of quantifying the Functional Impact Score in overall variant
 694 rankings.

695

696

697

698

699

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
B.1.617.2 +T95I	104	10	114
B.1.1.529 (Omicron) (Now BA.1)	22	36	58
BA.1 + R346K	12	38	50
BA.1 + A701V	2	36	38
BA.1_K417_ + N440_ + G446_	7	29	36
BA.1 + I1081V	0	36	36
BA.3	0	35	35
BA.2	1	34	35
BA.1 + R346K_K417_ + N440_ + G446_	3	31	34
BA.1_K417_ + N440_ + G446_ + L452 + RA701V	0	32	32
BA.1_K417_ + N440_ + G446_ + L452R	0	32	32
BA.2_K417_ + N440_	0	30	30
BA.1_K417_ + N440_ + G446_ + I1081V	0	29	29
BA.3_K417_ + N440_ + G446_	0	28	28

700

701

Figure 6 – Global Spike Variant Ranking for a User Supplied Annotated List with the

702

Composite Score. The output ranking from the *Composite Score* of an inputted list of

703

covariates, annotated with names based on the additional or lost mutations relative to a

704

consensus variant constellation, using GISAID data up to January 2022. These naming

705

annotations offer simpler representations of the covariate sequence. The scoring in the last

706

three columns quantitatively capture how these covariates differ, including the increase in

707

functional impact for BA.1 + R346K relative to the ancestral BA.1.

708

709

710

711

712

713

(A)

RBD Ranking	
Variant	Mutation Prevalence Score
T478K	64
L452R	34
G339D	30
E484A	26
S477N	26
S373P	25
S375F	25
Q493R	24
N501Y	23
S371L	20
Q498R	20
G496S	20
K417N	20
Y505H	19
N440K	18
G446S	18
R346K	15
S371F	2
T376A	2
R408S	2
D405N	2

(B)

NTD Ranking	
Variant	Mutation Prevalence Score
G142D	64
T95I	63
T19R	34
F157-	34
R158-	34
E156G	34
Y144-	30
V143-	30
H69-	29
V70-	29
A67V	28
Y145-	28
N211-	26
L212I	26
T19I	3
A222V	3
Y145H	3
A27S	3
V213G	2
P25-	1
L24-	1
P26-	1

723 **Figure 7 – Global Single Amino Acid Mutation Ranking with the *Mutation Prevalence***
724 **Score. (A)** The output of an RBD mutation ranking and **(B)** the output of an NTD mutation
725 ranking based on GISAID data up to December 2021. The results return a ranking for Spike
726 protein amino acid mutations ranked by the *Mutation Prevalence Score* within their respective
727 domain, RBD or NTD.

728

(A)

December 2021 Ranking		
WHO Label	PANGO Lineage	Emerging Lineage Score
Omicron	BA.1	57
Delta	AY.43	14
Delta	AY.122	12
Delta	AY.4	10
Delta	B.1.617.2	6
Delta	AY.127	4
Delta	AY.121	4
Delta	AY.4.2	3
Delta	AY.126	2
Delta	AY.39.1	2
Delta	AY.3	2
Delta	AY.25	2
Delta	AY.43.4	2
Delta	AY.39.1.1	2
Delta	AY.46.6	1
Delta	AY.29	1
Delta	AY.4.2.3	1
Delta	AY.4.5	1
Delta	AY.123	1
Delta	AY.119	1
Delta	AY.85	1
Delta	AY.36	1
Delta	AY.39	1
Delta	AY.58	1
Delta	AY.111	1

(B)

January 2022 Ranking		
WHO Label	PANGO Lineage	Emerging Lineage Score
Omicron	BA.1	103
Omicron	BA.1.1	46
Omicron	BA.2	15
Delta	AY.122	3
Delta	AY.4	3
Delta	AY.69	1
Delta	AY.43	1
Delta	AY.39.1.1	1
Delta	B.1.617.2	1
Delta	AY.4.2.3	1
Delta	AY.102	1
Delta	AY.36	1
Delta	AY.39.1	1
Delta	AY.111	1
Delta	AY.132	1

740 **Figure 8 – PANGO Lineage Ranking with the *Emerging Lineage Score*.** The output of a
 741 lineage ranking based on GISAID data up to December 2021 **(A)** and January 2022 **(B)**. The
 742 results return a global ranking of PANGO Lineages based on the *Emerging Lineage Score*. In
 743 December 2021, BA.1 was the strongest emerging lineage with other Delta sub-lineages still on
 744 the rise. However, by January 2022, several Omicron lineages were newly emerging, with the
 745 Delta lineages tapering off.

746

747

748


749

750

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	13	34	47
T19I,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	34	36
T19I,L24-,P25-,P26-,A27S,G142D,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	34	36
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	33	35
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,G798D,Q954H,N969K	1	34	35
T19I,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	33	35
T19I,L24-,P25-,P26-,A27S,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	33	34
T19I,L24-,P25-,P26-,A27S,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	32	33
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	32	33
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	31	32
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	25	26
T19I,L24-,P25-,P26-,A27S,G142D,V213G,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	24	25
T19I,L24-,P25-,P26-,A27S,G142D,V213G,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	24	25
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	2	14	16
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	15	16
T19I,L24-,P25-,P26-,A27S,G142D,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	14	15
L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	1	13	14


751
 752 **Figure 9 – Global Ranking of BA.2 Variants with the Composite Score.** The output of a
 753 *Composite Score* ranking based on GISAID data up to January 2022. The purpose of this
 754 ranking is to focus the analysis on covariates within a specific lineage, in this case within BA.2.
 755 The ability to capture a dominant covariate (top row) likely driving much of the observed
 756 dynamics for this lineage can be observed.
 757

758 (A)



759


760 (B)




761

762 **Figure 10 – Visualizing the Emergence of the Delta (B.1.617.2) Variant.** (A) A plot of global
763 trends overtime based on GISAID data up to June 2021 to visualize the early growth dynamics
764 of Delta. The graph displays the 10 PANGO lineages with the most substantial global

765 prevalence dynamics over a six-month time frame, with the early emergence of B.1.671.2 and
766 the sudden sharp decline of B.1.1.7 clearly evident. **(B)** A plot of growth trends for Delta in the
767 United Kingdom based on GISAID data up to June 2021. The graph displays the PANGO
768 lineages with the most substantial global prevalence dynamics over a six-month time frame
769 solely within the United Kingdom and shows the local growth of B.1.617.2 and decline of
770 B.1.1.7.
771
772



773
774 **Figure 11 – Visualizing the Emergence of Omicron Variant Constellations.** A plot displaying
775 the prevalence dynamics over six months of Spike covariates in an inputted file based on
776 GISAID data up to January 2022. This visualization captures the sharp growth and relatively
777 large global prevalence of BA.1 + R346K. The names presented in the legend mean the
778 ancestral PANGO lineage +/- certain amino acid mutations to represent different covariates.
779 Underscores indicate that certain mutations were lost relative to the ancestral sequence.



780

781 **Figure 12 – Visualizing Growth Patterns of Single Amino Acid Mutations in the Spike**
782 **Protein.** A plot based on GISAID data up to March 2022 demonstrating the shift in dynamics
783 for individual amino acid mutations. This plot is based on an inputted list of six amino acid
784 mutations. Note that the L24- is a part of an extended deletion that also includes P25 and P26
785 found in BA.2.

786

787

788

789

790

791

792

793

794


WHO Label	Variant	Sequence Prevalence Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5
Delta	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3
Omicron	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2

Region4
Receptor-binding domain (RBD)

Region5
Integrin-binding motif;

Region6
Receptor-binding motif; binding to human ACE2

Class 1
Class 2
Class 3
Class 4



B.1.1.529 : G339D

B.1.1.529 : S371L

B.1.1.529 : S373P

B.1.1.529 : S375F

B.1.1.529 : K417N

B.1.351+B.1.351.*lineages : K417N

P.1+P.1.*lineages : K417T

B.1.1.529 : G446S

B.1.1.529 : N440K

B.1.617.2+AY.*lineages : L452R

B.1.1.529 : S477N

B.1.1.529 : T478K

B.1.617.2+AY.*lineages : T478K

B.1.1.529 : E484A

B.1.351+B.1.351.*lineages : E484K

P.1+P.1.*lineages : E484K

B.1.1.529 : Q493R

B.1.1.529 : Q498R

B.1.1.7+Q.*lineages : N501Y

B.1.351+B.1.351.*lineages : N501Y



P.1+P.1.*lineages : N501Y

B.1.1.529 : N501Y


B.1.1.529 : Y505H

B.1.1.529 : G496S

Distribution of Antibody and Serum Escape Fractions from Deep Mutational Scanning



Distribution of ACE2 Binding Scores from Deep Mutational Scanning



WHO Label	Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	161	10	171
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	118	10	128
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	98	9	107
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	42	9	51
Omicron	A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P, S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H, T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	2	36	38
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	22	10	32
Delta	T19R,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	17	11	28
Delta	T19R,L452R,T478K,D614G,P681R,D950N	13	7	20
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	8	10	18
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,G1167V	8	10	18
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R	9	9	18
Delta	T19R,G142D,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	8	10	18
Delta	T19R,G142D,L452R,T478K,D614G,P681R,D950N	9	8	17
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,T859I,D950N	5	11	16
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	6	10	16
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	6	10	16
Delta	L5F,T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	7	9	16
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,A701S,D950N,A1078S	5	10	15
Delta	T19R,G142D,E156G,F157-,R158-,A411S,L452R,T478K,D614G,P681R,D950N	5	10	15
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,D950N	6	9	15
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	5	10	15
Delta	L5F,T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	5	10	15
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T719I,L938F,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,T716I,D950N	4	10	14
Delta	T19R,A67V,G142D,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	4	10	14
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,T572I,D614G,P681R,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,S680P,P681R,D950N	3	11	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1264L	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,A222V,L452R,T478K,Q613H,D614G,P681R,D950N	4	10	14
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	5	9	14
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,S929T,D950N	4	10	14
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,A845S,D950N,V1264L	4	10	14
Delta	L5F,T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N	4	10	14
Delta	T19R,V36F,T95I,G142D,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	11	14
Delta	T19R,T95I,G142D,E156G,F157-,R158-,L452R,T478K,D614G,Q677H,P681R,D950N	3	11	14
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,K1073N	4	9	13
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	4	9	13
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,A570S,D614G,P681R,D950N	3	10	13
Delta	T19R,G142D,E156G,F157-,R158-,L452R,T478K,Q613H,D614G,P681R,D950N	3	10	13
Delta	T19R,T95I,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	4	9	13
Delta	T19R,T95I,G142D,E156G,F157-,R158-,D178N,L452R,T478K,D614G,P681R,D950N	3	10	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,I850L,D950N	4	9	13
Delta	T19R,T95I,Y145H,E156G,F157-,R158-,A222V,L452R,T478K,D614G,P681R,D950N	3	10	13
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,D1259Y	3	9	12
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950N,V1104L	3	9	12
Delta	T19R,E156G,F157-,R158-,L452R,T478K,D614G,P681R,D950B	3	9	12
Delta	T19R,E156G,F157-,R158-,G181V,L452R,T478K,D614G,P681R,D950N	3	9	12
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950B	4	7	11
Delta	T19R,L244S,L452R,T478K,T572I,D614G,P681R,D950N	3	7	10
Delta	T19R,E156G,F157-,R158-,D614G,P681R,D950N	3	5	8

Variant	Sequence Prevalence Score	Functional Impact Score	Composite Score
B.1.617.2 +T95I	104	10	114
B.1.1.529 (Omicron) (Now BA.1)	22	36	58
BA.1 + R346K	12	38	50
BA.1 + A701V	2	36	38
BA.1_K417_ + N440_ + G446_	7	29	36
BA.1 + I1081V	0	36	36
BA.3	0	35	35
BA.2	1	34	35
BA.1 + R346K_K417_ + N440_ + G446_	3	31	34
BA.1_K417_ + N440_ + G446_ + L452 + RA701V	0	32	32
BA.1_K417_ + N440_ + G446_ + L452R	0	32	32
BA.2_K417_ + N440_	0	30	30
BA.1_K417_ + N440_ + G446_ + I1081V	0	29	29
BA.3_K417_ + N440_ + G446_	0	28	28

RBD Ranking

Variant	Matation Prevalence Score
T478K	64
L452R	34
G339D	30
E484A	26
S477N	26
S373P	25
S375F	25
Q493R	24
N501Y	23
S371L	20
Q498R	20
G496S	20
K417N	20
Y505H	19
N440K	18
G446S	18
R346K	15
S371F	2
T376A	2
R408S	2
D405N	2

NTD Ranking

Variant	Mutation Prevalence Score
G142D	64
T95I	63
T19R	34
F157-	34
R158-	34
E156G	34
Y144-	30
V143-	30
H69-	29
V70-	29
A67V	28
Y145-	28
N211-	26
L212I	26
T19I	3
A222V	3
Y145H	3
A27S	3
V213G	2
P25-	1
L24-	1
P26-	1

December 2021 Ranking


WHO Label	PANGO Lineage	Emerging Lineage Score
Omicron	BA.1	57
Delta	AY.43	14
Delta	AY.122	12
Delta	AY.4	10
Delta	B.1.617.2	6
Delta	AY.127	4
Delta	AY.121	4
Delta	AY.4.2	3
Delta	AY.126	2
Delta	AY.39.1	2
Delta	AY.3	2
Delta	AY.25	2
Delta	AY.43.4	2
Delta	AY.39.1.1	2
Delta	AY.46.6	1
Delta	AY.29	1
Delta	AY.4.2.3	1
Delta	AY.4.5	1
Delta	AY.123	1
Delta	AY.119	1
Delta	AY.85	1
Delta	AY.36	1
Delta	AY.39	1
Delta	AY.58	1
Delta	AY.111	1

January 2022 Ranking


WHO Label	PANGO Lineage	Emerging Lineage Score
Omicron	BA.1	103
Omicron	BA.1.1	46
Omicron	BA.2	15
Delta	AY.122	3
Delta	AY.4	3
Delta	AY.69	1
Delta	AY.43	1
Delta	AY.39.1.1	1
Delta	B.1.617.2	1
Delta	AY.4.2.3	1
Delta	AY.102	1
Delta	AY.36	1
Delta	AY.39.1	1
Delta	AY.111	1
Delta	AY.132	1

Variant	Sequence Prevalence Score
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	74
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	57
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,D796Y,N856K,Q954H,N969K,L981F	16
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	15
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	13
T19I,L24-,P25-,P26-,A27S,G142D,V213G,G339D,S371F,S373P,S375F,T376A,D405N,R408S,K417N,N440K,S477N,T478K,E484A,Q493R,Q498R,N501Y,Y505H,D614G,H655Y,N679K,P681H,N764K,D796Y,Q954H,N969K	13
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,D796Y,N856K,Q954H,N969K,L981F	12
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	12
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,G339D,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	10
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	9
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	9
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,G339D,R346K,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	9
G339D,R346K,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	8
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	8
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,R346K,S371L,S373P,S375F,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	7
A67V,H69-,V70-,T95I,G142D,V143-,Y144-,Y145-,N211-,L212I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,F643L,H655Y,N679K,P681H,A701V,N764K,D796Y,N856K,Q954H,N969K,L981F	6
A67V,T95I,G339D,S371L,S373P,S375F,K417N,N440K,G446S,S477N,T478K,E484A,Q493R,G496S,Q498R,N501Y,Y505H,T547K,D614G,H655Y,N679K,P681H,N764K,D796Y,N856K,Q954H,N969K,L981F	5


A Time Course of Lineage Proportions from Sequence Isolates Extracted in World



A Time Course of Lineage Proportions from Sequence Isolates Extracted in United Kingdom



A Time Course of User Inputted Covariate Prevalence Ratios from Sequences Isolated in World



A Time Course of Prevalence Ratios for User Inputted Mutations from Sequences Isolated in World

